Evolution of the serologic and virologic course of occult HBV infection in therapy experienced HIV co-infected patients

被引:4
|
作者
Amponsah-Dacosta, Edina [1 ,2 ]
Selabe, Selokela G. [1 ,2 ]
Mphahlele, Maphahlaganye J. [1 ,2 ,3 ]
机构
[1] Sefako Makgatho Hlth Sci Univ, Dept Virol, HIV & Hepatitis Res Unit, ZA-0204 Pretoria, South Africa
[2] Natl Hlth Lab Serv, Pretoria, South Africa
[3] South African Med Res Council, Pretoria, South Africa
基金
英国医学研究理事会; 新加坡国家研究基金会;
关键词
antiviral agents; genetic variability; hepatitis B virus; human immunodeficiency virus; reactivation; superinfection; HEPATITIS-B-VIRUS; CLINICAL-SIGNIFICANCE; FUNCTIONAL-ANALYSIS; COINFECTION; ANTIGEN; DNA;
D O I
10.1002/jmv.24956
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We investigated how the natural course of occult hepatitis B virus (HBV) infection (OBI) may evolve during HIV co-infection and long term HBV-active HAART. From a cohort of 181 HIV infected patients who were consecutively recruited over a 5 year period, 28 HBV co-infected patients with sequential sera (n=98) were identified. Iterative HBV serology and viral loads were determined before and during treatment. The viral HBsAg gene was then serially amplified, directly sequenced, and molecularly characterized. Persistent detection of anti-HBs did not result in a modification to the clinical course of OBI. In contrast, reactivation of chronic HBV infection, hepatic enzymatic flares and cases of HBV reinfection were evident among anti-HBs negative OBI patients, and this was a notable finding. Of the 14 chronic HBV infected patients, eight progressed to persistent OBI after initiation of HBV-active HAART, increasing the number of patients with OBI in the study. Long term HBV-active HAART was not found to have a notable impact on low level viremia during OBI. While the HBsAg gene sequences isolated from chronic HBV infection were genetically stable over time, OBI-associated variants (sP111R, sT127P, sY161F) were neither stable nor predominant during the course of infection. This study is the first of its kind from South Africa to show the occurrence of hepatic enzymatic flares, HBV reactivation, and reinfection in HAART-exposed HIV co-infected patients with OBI. Among the cases studied, there was further evidence that OBI-associated variants may not play a significant role in the pathogenesis of OBI.
引用
收藏
页码:291 / 303
页数:13
相关论文
共 50 条
  • [31] BCP/PC mutation prevalence and their association with HBV replication in HIV/HBV co-infected patients
    Dongdong Li
    Qixia Chen
    Chuanmin Tao
    Archives of Virology, 2018, 163 : 2829 - 2833
  • [32] Biochemical and virologic parameters in patients co-infected with hepatitis C and HIV versus patients with hepatitis C mono-infection
    Butt, Adeel A.
    Tsevat, Joel
    Ahmad, Jawad
    Shakil, A. Obaid
    Mrus, Joseph M.
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2007, 333 (05): : 271 - 275
  • [33] Management of patients co-infected with HBV and HCV
    Coffin, Carla S.
    Terrault, Norah A.
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2009, 7 (05) : 549 - 558
  • [34] Reactivation of occult HBV infection in an HIV/HCV Co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature
    Fabbri, Gabriele
    Mastrorosa, Ilaria
    Vergori, Alessandra
    Mazzotta, Valentina
    Pinnetti, Carmela
    Grisetti, Susanna
    Zaccarelli, Mauro
    Ammassari, Adriana
    Antinori, Andrea
    BMC INFECTIOUS DISEASES, 2017, 17
  • [35] Reactivation of occult HBV infection in an HIV/HCV Co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature
    Gabriele Fabbri
    Ilaria Mastrorosa
    Alessandra Vergori
    Valentina Mazzotta
    Carmela Pinnetti
    Susanna Grisetti
    Mauro Zaccarelli
    Adriana Ammassari
    Andrea Antinori
    BMC Infectious Diseases, 17
  • [37] Low rate of delayed response in lamivudine experienced HIV/HBV co-infected patients treated with tenofovir disoproxil fumarate (TDF)
    Lada, O.
    Gervais, A.
    Branger, M.
    Peytavin, G.
    Colin, G.
    Fraqueiro, G.
    Males, S.
    Martinot-Peignoux, M.
    Matheron, S.
    Marcellin, P.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S259 - S259
  • [38] Serologic and virologic response to hepatitis B vaccination among patients with occult hepatitis B virus (HBV) infection.
    Pereira, JS
    Silva, C
    Goncales, N
    Fais, V
    Thomaz, G
    Lazarini, MS
    Pavan, MH
    Goncales, F
    HEPATOLOGY, 2002, 36 (04) : 614A - 614A
  • [39] Telaprevir combination therapy in treatment-naive and -experienced patients co-infected with HCV/HIV (INSIGHT STUDY): sustained virologic response at 12 weeks final analysis
    Montes, Marisa L.
    Nelson, Mark
    Girard, Pierre-Marie
    Sasadeusz, Joe
    Horban, Andrzej
    Grinsztejn, Beatriz
    Zakharova, Natalia
    Rivero, Antonio
    Lathouwers, Erkki
    Janssen, Katrien
    Ouwerkerk-Mahadevan, Sivi
    Witek, James
    HEPATOLOGY, 2014, 60 : 678A - 678A
  • [40] Hepatitis D Virus Infection among HIV-HBV Co-Infected Patients in Kermanshah, West of Iran
    Vaziri, Siavash
    Mansouri, Feizollah
    Sayad, Babak
    Afsharian, Mandana
    Janbakhsh, Afireza
    Karami, Manoochehr
    HEPATITIS MONTHLY, 2008, 8 (04) : 252 - 257